1. In Vivo

Best of the Blog: IN VIVO, June 2008

In May, Windhover's editorial staff posted 35 articles to the blog, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Here are a few of our favorite posts that didn't make it into stories covered elsewhere in this month's magazine: Changing of the Change Agents: Exit Wyeth's Ruffolo, Enter Orbimed's Dolsten; Cimzia Launch: Nothing Simple About It; Lundbeck Thanks Myriad For the Memories; Takeda's Millions Buy a Lot of Beer.

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May, Windhover’s editorial staff posted 35 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Last month we took an in-depth look at the FDA advisory committee review of Cephalon’s Fentora, interviewed some FDA brass, and analyzed the month’s important deals, from Takeda’s spree to BMS’ string of pearls. Here are a few of our favorite blog posts for stories not covered elsewhere in this month’s IN VIVO.

(May 1.) We just heard the news that Bob Ruffolo, Wyeth’s R&D boss, is retiring.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.